Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., ...

Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced ...

A live webcast link for the Leerink Partners Global Biopharma Conference fireside chat will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be ...

AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351 (k) biosimilar pathway, today announced that ...

A fireside chat at the Leerink Partners Global Healthcare Conference, in Miami on Tuesday, March 11, 2025, at 4:20 p.m. ET. A ...

Stock analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Schrödinger in a research report issued to clients and investors on Wednesday, February 26th. Leerink ...

Equities research analysts at Leerink Partnrs issued their FY2026 EPS estimates for Kura Oncology in a note issued to investors on Wednesday, February 26th. Leerink Partnrs analyst J. Chang ...

Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced ...

The webcast of the fireside chat will be accessible in the investor section of 89bio’s website. A replay of the webcast will be available for approximately 30 days following the conference.

AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...

Leerink Partners and Piper Sandler are acting as joint bookrunning managers for the proposed offering.

Savara Inc. (Nasdaq: SVRA ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will attend the Leerink ...